Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial

BACKGROUND: De-escalating anthracycline is gaining popularity for breast cancer patients. We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ke-Da, Liu, Xi-Yu, Chen, Li, Mo, Miao, Wu, Jiong, Liu, Guang-Yu, Di, Gen-Hong, Verschraegen, Claire, Stover, Daniel G., Zhuang, Zhi-Gang, Bertucci, François, Orlandi, Armando, Wang, Jie, Lippi, Giuseppe, Wu, Ke-Jin, Osman, Mohammed A., Fan, Lei, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315472/
https://www.ncbi.nlm.nih.gov/pubmed/34327363
http://dx.doi.org/10.1016/j.lanwpc.2021.100158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315472/
https://www.ncbi.nlm.nih.gov/pubmed/34327363
http://dx.doi.org/10.1016/j.lanwpc.2021.100158

Ejemplares similares